Andy Ai Ni, PhD

Andy Ai Ni, PhD
Assistant Professor
Biostatistics
Phone: 614-292-5482
Email: ni.304@osu.edu
1841 Neil Ave.
280D Cunz Hall
Columbus, OH 43210

Background:

Dr. Ni’s methodological research interests are in the design and analysis of large-scale observational studies with survival outcomes. He is particularly interested in regularized variable selection and optimal treatment regimen estimation in survival analysis under case-cohort and nested case-control designs. He collaborates with faculty at the College of Dentistry on the design and analysis of various observational studies and clinical trials.

Research Interests:

High-dimensional variable selection with survival outcomes, Individualized treatment regimen estimation with survival outcomes; Outcome-dependent sampling designs; High-dimensional variable selection with measurement error

Education:

Ph.D., Biostatistics, University of North Carolina at Chapel Hill, 2015
M.S., Biostatistics, University of Toronto, 2008
M.S., Biochemistry and Molecular Biology, University of Calgary, 2005
B.S., Biology Engineering, Xi'an Jiaotong University, 2002

Selected Publications:

PubMed listing

Methodology 

A. Ni and J. Cai. “Tuning parameter selection in Cox proportional hazards model with a diverging number of parameters.” Scandinavian Journal of Statistics. 2018; 45(3): 557-570.

A. Ni and J. Cai. “A regularized variable selection procedure in additive hazards model with stratified case-cohort design.” Lifetime Data Analysis. 2018; 24(3): 443-463.

A. Ni, J. Cai, D. Zeng. “Variable selection for case-cohort studies with failure time outcome”. Biometrika. 2016; 103 (3): 547-562. [R package

Collaboration

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O. “Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018; 13(10):1595-1601.

Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, Ni A, Yahalom J, Moskowitz CH. “Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.” Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018; 24(10):2133-2138.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. “Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018; 36(28):2872-2878.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. “Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018; 36(24):2532-2537.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD. “Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;

Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M. “Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.” Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(13):3108-3118.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. “Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018; 36(7):633-641.

Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ. “Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(2):334-340. NIHMSID: NIHMS917304

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. “Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.” Blood. 2017; 130(20):2196-2203.

LaVange L, Davis SM, Hankinson J, Enright P, Wilson R, Barr RG, Aldrich TK, Kalhan R, Lemus H, Ni A, Smith LJ, Talavera GA. “Spirometry Reference Equations from the HCHS/SOL (Hispanic Community Health Study/Study of Latinos).” American journal of respiratory and critical care medicine. 2017; 196(8):993-1003.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ. “Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.” Cancer discovery. 2017; 7(6):596-609. NIHMSID: NIHMS863885

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. “PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research. 2017; 23(2):523-535. NIHMSID: NIHMS805217